The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.

Abstract excerpt

B-cell receptors, multiple receptor tyrosine kinases, and downstream effectors are constitutively active in chronic lymphocytic leukemia (CLL) B cells. Activation of these pathways results in resistance to apoptosis and enhanced survival of the leukemic cells. Idelalisib is a highly selective inhibitor of the PI3K p110∂ isoform and is approved for the treatment of CLL in patients with relapsed/refractory disease...

Topics

Join the communities discussing this publication.

• Chromosome Aberrations
• Immunocompromised Host
• Killer Cells, Natural
• Leukemia, Lymphocytic, Chronic, B-Cell
• Lymphocyte Activation